Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology

Background and Aims : Chronic hepatitis C is a slowly progressing inflammatory disease of the liver that can lead to cirrhosis and its complications. Assessment of liver damage in hepatitis C has been primarily via histological evaluation. Liver biopsy, while useful in determining the extent of liver damage, has associated costs and places patients at a small but finite risk of bleeding. Studies in small patient populations have identified serum markers shown to correlate with liver histology, including pro‐collogen III peptide and hyaluronic acid (HA). To determine whether serum HA was a reliable predictor of cirrhosis and fibrosis, we examined serum HA concentrations from 486 chronic Hepatitis C virus (HCV) patients.

[1]  A. Engström‐Làurent,et al.  Serum hyaluronate in primary biliary cirrhosis—A biochemical marker for progressive liver damage , 1988, Hepatology.

[2]  M. Vidaud,et al.  Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.

[3]  B. Balkau,et al.  Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. , 1994, Journal of hepatology.

[4]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[5]  J. Hoefs,et al.  Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial , 1997 .

[6]  A. Zanetti,et al.  Does immunoglobulin interfere with the immunogenicity to Pasteur Mérieux inactivated hepatitis A vaccine? , 1997, Journal of hepatology.

[7]  G. Rassidakis,et al.  Histopathology of chronic hepatitis C in relation to epidemiological factors. , 1996, Journal of hepatology.

[8]  R. Poupon,et al.  Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. , 1995, Journal of hepatology.

[9]  J. McHutchison,et al.  Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison , 1997, Hepatology.

[10]  A. Burroughs,et al.  Liver transplantation for chronic viral hepatitis. , 1991, The Italian journal of gastroenterology.

[11]  Z. Younossi,et al.  Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C , 1999, Hepatology.

[12]  K. Murata,et al.  Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. , 1985, Gastroenterology.

[13]  A. Gressner,et al.  Hyaluronic acid synthesis and secretion by rat liver fat storing cells (perisinusoidal lipocytes) in culture. , 1988, Biochemical and biophysical research communications.

[14]  T. Kashiwagi,et al.  Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C , 1996, Hepatology.

[15]  M. Koffler.  Epidemiology of hepatitis. , 1965, Lancet.

[16]  H. Kawasaki,et al.  Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. , 1995, Journal of hepatology.

[17]  S. Hwang,et al.  Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma. , 1994, The Western journal of medicine.

[18]  T. Terada,et al.  Profiles of expression of carbohydrate chain structures during human intrahepatic bile duct development and maturation: A lectin‐histochemical and immunohistochemical study , 1994, Hepatology.

[19]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[20]  P. Bedossa,et al.  Noninvasive diagnosis of hepatic fibrosis or cirrhosis. , 1997, Gastroenterology.

[21]  L. Serfaty,et al.  Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. , 1996, Clinical chemistry.

[22]  M. Alter,et al.  Epidemiology of Hepatitis C in the West , 1995, Seminars in liver disease.

[23]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[24]  G. Davis,et al.  Factors predictive of a beneficial response to therapy of hepatitis C , 1997, Hepatology.

[25]  J. Rodés,et al.  Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis , 1996, Hepatology.

[26]  T. Laurent,et al.  Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. , 1981, The Biochemical journal.

[27]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[28]  O. Weiland,et al.  Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. , 1999, Gastroenterology.

[29]  H. Kawasaki,et al.  Clinical significance of serum hyaluronan in patients with chronic viral liver disease , 1996, Journal of gastroenterology and hepatology.